Abstract
The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-alpha and IL-1 beta. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo.
MeSH terms
-
Catalysis
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / pharmacology*
-
Imidazoles / chemical synthesis*
-
Imidazoles / pharmacology*
-
Indicators and Reagents
-
Mitogen-Activated Protein Kinases / antagonists & inhibitors*
-
Pyrimidines / chemical synthesis
-
Pyrimidines / pharmacology
-
Structure-Activity Relationship
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
p38 Mitogen-Activated Protein Kinases
Substances
-
Enzyme Inhibitors
-
Imidazoles
-
Indicators and Reagents
-
Pyrimidines
-
Tumor Necrosis Factor-alpha
-
Mitogen-Activated Protein Kinases
-
p38 Mitogen-Activated Protein Kinases